
    
      This is a Phase 1 open-label study in healthy volunteers who will receive oral 200 mg TR 701
      FA once daily for 10 days (Days 1 through 10) and undergo safety evaluations including
      ophthalmologic and neurologic assessments before (Screening or Day -1), 1 day after final
      study drug administration (Day 11 or earlier if a subject discontinues treatment), and 2 to 4
      weeks after the last study drug administration (Late Follow-up Visit).
    
  